Feasibility and effectiveness of extended-release buprenorphine (XR-BUP) among correctional populations: a systematic review.

Autor: Russell C; Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.; Ontario Node, Canadian Research Initiative in Substance Misuse (CRISM), Toronto, ON, Canada., George TP; Institute of Medical Science (IMS), University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Addictions Division, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada., Chopra N; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Addictions Division, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada., Le Foll B; Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.; Ontario Node, Canadian Research Initiative in Substance Misuse (CRISM), Toronto, ON, Canada.; Institute of Medical Science (IMS), University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Addictions Division, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.; Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.; Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.; Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.; Waypoint Research Institute, Waypoint Centre for Mental Health Care, Penetanguishene, ON, Canada., Matheson FI; Institute of Medical Science (IMS), University of Toronto, Toronto, ON, Canada.; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.; MAP Centre for Urban Health Solutions, St. Michael's Hospital, a site of Unity Health Toronto, Toronto, ON, Canada.; Centre for Criminology & Sociolegal Studies, University of Toronto, Toronto, ON, Canada., Rehm J; Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.; Ontario Node, Canadian Research Initiative in Substance Misuse (CRISM), Toronto, ON, Canada.; Institute of Medical Science (IMS), University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.; Institut für Klinische Psychologie und Psychotherapie, Technische Universität Dresden, Dresden, Germany.; Center for Interdisciplinary Addiction Research (ZIS), Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany., Lange S; Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.; Institute of Medical Science (IMS), University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.
Jazyk: angličtina
Zdroj: The American journal of drug and alcohol abuse [Am J Drug Alcohol Abuse] 2024 Jun 28, pp. 1-20. Date of Electronic Publication: 2024 Jun 28.
DOI: 10.1080/00952990.2024.2360984
Abstrakt: Background: Medications for opioid use disorder (MOUD) reduce risks for overdose among correctional populations. Among other barriers, daily dosing requirements hinder treatment continuity post-release. Extended-release buprenorphine (XR-BUP) may therefore be beneficial. However, limited evidence exists. Objectives: To conduct a systematic review examining the feasibility and effectiveness of XR-BUP among correctional populations. Methods: Searches were carried out in Pubmed, Embase, and PsychINFO in October 2023. Ten studies reporting on feasibility or effectiveness of XR-BUP were included, representing n  = 819 total individuals (81.6% male). Data were extracted and narratively reported under the following main outcomes: 1) Feasibility; 2) Effectiveness; and 3) Barriers and Facilitators. Results: Studies were heterogeneous. Correctional populations were two times readier to try XR-BUP compared to non-correctional populations. XR-BUP was feasible and safe, with no diversion, overdoses, or deaths; several negative side effects were reported. Compared to other MOUD, XR-BUP significantly reduced drug use, resulted in similar or higher treatment retention rates, fewer re-incarcerations, and was cost-beneficial, with a lower overall monthly/yearly cost. Barriers to XR-BUP, such as side effects and a fear of needles, as well as facilitators, such as a lowered risk of opioid relapse, were also identified. Conclusion: XR-BUP appears to be a feasible and potentially effective alternative treatment option for correctional populations with OUD. XR-BUP may reduce community release-related risks, such as opioid use and overdose risk, as well as barriers to treatment retention. Efforts to expand access to and uptake of XR-BUP among correctional populations are warranted.
Databáze: MEDLINE